Baseline patient characteristics and their association with bleeding and thrombosis
| Patient baseline characteristics . | Total . | Bleeding . | P . | Thrombosis . | P . | ||
|---|---|---|---|---|---|---|---|
| Yes (n = 12) . | No (n = 115) . | Yes (n = 8) . | No (n = 119) . | ||||
| Sex, n (%) | .21 | .99 | |||||
| Male | 82 | 10 (83.3) | 72 (62.6) | — | 5 (62.5) | 77 (64.8) | — |
| Female | 45 | 2 (16.7) | 43 (37.4) | — | 3 (37.5) | 42 (35.2) | — |
| Age, y, median (range) | 61 (21-82) | 72 (58-77) | 60 (21-82) | <.01 | 67.5 (21-76) | 61 (25-82) | .47 |
| Diagnosis, n (%) | |||||||
| DLBCL | 111 | 11 (91.7) | 100 (87) | .99 | 7 (87.5) | 104 (87.4) | .99 |
| ALL | 16 | 1 (8.3) | 15 (13) | — | 1 (12.5) | 15 (12.6) | — |
| Disease burden markers, n (%) | |||||||
| Elevated baseline LDH | 61 | 10 (83.3) | 51 (44.3) | .01 | 4 (50) | 57 (47.9) | .99 |
| BM blasts (ALL) >5%, n (%) | 7 | 1 (8.3) | 6 (5.2) | .51 | 1 (12.5) | 6 (5) | .37 |
| Baseline platelets, ×103/μL, median (range) | 174 (8-483) | 86 (8-219) | 178 (24-483) | <.01 | 207 (134-311) | 174 (8-483) | .11 |
| Prior lines of therapy, n median (range) | 3 (2-12) | 3 (2-4) | 3 (2-12) | .71 | 3 (2-5) | 3 (2-12) | .29 |
| Prior transplant, n (%)* | 38 | 2 (16.7) | 36 (31.3) | .51 | 1 (12.5) | 37 (31.1) | .43 |
| Bridging therapy, n (%) | 26 | 5 (41.7) | 21 (18.3) | .07 | 3 (37.5) | 23 (19.3) | .36 |
| History of bleeding, n | 4 | 3 (25) | 1 (0.8) | <.01 | 0 (0) | 4 (3.4) | .99 |
| History of clotting, n | 25 | 4 (33.3) | 21 (18.3) | .25 | 3 (37.5) | 22 (18.4) | .19 |
| Neurologic comorbidity, n | 7 | 1 (8.3) | 6 (5.2) | .51 | 2 (25) | 5 (4.2) | .06 |
| Vascular comorbidity, n | 12 | 2 (16.7) | 10 (8.7) | .32 | 2 (25) | 10 (8.4) | .17 |
| Anticoagulation (preceding CAR T), n | 9 | 1 (8.3) | 8 (7) | .99 | 0 (0) | 9 (7.6) | .99 |
| Patient baseline characteristics . | Total . | Bleeding . | P . | Thrombosis . | P . | ||
|---|---|---|---|---|---|---|---|
| Yes (n = 12) . | No (n = 115) . | Yes (n = 8) . | No (n = 119) . | ||||
| Sex, n (%) | .21 | .99 | |||||
| Male | 82 | 10 (83.3) | 72 (62.6) | — | 5 (62.5) | 77 (64.8) | — |
| Female | 45 | 2 (16.7) | 43 (37.4) | — | 3 (37.5) | 42 (35.2) | — |
| Age, y, median (range) | 61 (21-82) | 72 (58-77) | 60 (21-82) | <.01 | 67.5 (21-76) | 61 (25-82) | .47 |
| Diagnosis, n (%) | |||||||
| DLBCL | 111 | 11 (91.7) | 100 (87) | .99 | 7 (87.5) | 104 (87.4) | .99 |
| ALL | 16 | 1 (8.3) | 15 (13) | — | 1 (12.5) | 15 (12.6) | — |
| Disease burden markers, n (%) | |||||||
| Elevated baseline LDH | 61 | 10 (83.3) | 51 (44.3) | .01 | 4 (50) | 57 (47.9) | .99 |
| BM blasts (ALL) >5%, n (%) | 7 | 1 (8.3) | 6 (5.2) | .51 | 1 (12.5) | 6 (5) | .37 |
| Baseline platelets, ×103/μL, median (range) | 174 (8-483) | 86 (8-219) | 178 (24-483) | <.01 | 207 (134-311) | 174 (8-483) | .11 |
| Prior lines of therapy, n median (range) | 3 (2-12) | 3 (2-4) | 3 (2-12) | .71 | 3 (2-5) | 3 (2-12) | .29 |
| Prior transplant, n (%)* | 38 | 2 (16.7) | 36 (31.3) | .51 | 1 (12.5) | 37 (31.1) | .43 |
| Bridging therapy, n (%) | 26 | 5 (41.7) | 21 (18.3) | .07 | 3 (37.5) | 23 (19.3) | .36 |
| History of bleeding, n | 4 | 3 (25) | 1 (0.8) | <.01 | 0 (0) | 4 (3.4) | .99 |
| History of clotting, n | 25 | 4 (33.3) | 21 (18.3) | .25 | 3 (37.5) | 22 (18.4) | .19 |
| Neurologic comorbidity, n | 7 | 1 (8.3) | 6 (5.2) | .51 | 2 (25) | 5 (4.2) | .06 |
| Vascular comorbidity, n | 12 | 2 (16.7) | 10 (8.7) | .32 | 2 (25) | 10 (8.4) | .17 |
| Anticoagulation (preceding CAR T), n | 9 | 1 (8.3) | 8 (7) | .99 | 0 (0) | 9 (7.6) | .99 |
N = 127. Categorical variables were analyzed by Fisher’s exact test and continuous variables by the Mann-Whitney U test. Bold indicates statistically significant results. P values in bold are .05 or less.
BM, bone marrow; NHL, non-Hodgkin lymphoma.
Autograft (n = 26); allograft (n = 12).